|
1
|
Robins HI, Peterson CG and Mehta MP:
Combined modality treatment for central nervous system
malignancies. Semin Oncol. 30 Suppl 9:11–22. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cloughesy TF, Cavenee WK and Mischel PS:
Glioblastoma: From molecular pathology to targeted treatment. Annu
Rev Pathol. 9:1–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rao JS: Molecular mechanisms of glioma
invasiveness: The role of proteases. Nat Rev Cancer. 3:489–501.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Van Meter TE, Rooprai HK, Kibble MM,
Fillmore HL, Broaddus WC and Pilkington GJ: The role of matrix
metalloproteinase genes in glioma invasion: Co-dependent and
interactive proteolysis. J Neurooncol. 53:213–235. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yong VW: Metalloproteinases: Mediators of
pathology and regeneration in the CNS. Nat Rev Neurosci. 6:931–944.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yong VW, Power C, Forsyth P and Edwards
DR: Metallo-proteinases in biology and pathology of the nervous
system. Nat Rev Neurosci. 2:502–511. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mignatti P and Rifkin DB: Biology and
biochemistry of proteinases in tumor invasion. Physiol Rev.
73:161–195. 1993.PubMed/NCBI
|
|
8
|
Gao X, Wang X, Yang Q, Zhao X, Wen W, Li
G, Lu J, Qin W, Qi Y, Xie F, et al: Tumoral expression of IL-33
inhibits tumor growth and modifies the tumor microenvironment
through CD8+ T and NK cells. J Immunol. 194:438–445.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Forsyth PA, Wong H, Laing TD, Rewcastle
NB, Morris DG, Muzik H, Leco KJ, Johnston RN, Brasher PM,
Sutherland G, et al: Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and
membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in
different aspects of the pathophysiology of malignant gliomas. Br J
Cancer. 79:1828–1835. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kargiotis O, Chetty C, Gondi CS, Tsung AJ,
Dinh DH, Gujrati M, Lakka SS, Kyritsis AP and Rao JS:
Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in
impaired invasion and tumor-induced angiogenesis, induces apoptosis
in vitro and inhibits tumor growth in vivo in glioblastoma.
Oncogene. 27:4830–4840. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shastry AH, Thota B, Arimappamagan A and
Santosh V: P53 stratification reveals the prognostic utility of
matrix metalloproteinase-9 protein expression in glioblastoma.
Neurol India. 63:399–404. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Heimberger AB and Sampson JH:
Immunotherapy coming of age: What will it take to make it standard
of care for glioblastoma? Neuro-oncol. 13:3–13. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Palmer G and Gabay C: Interleukin-33
biology with potential insights into human diseases. Nat Rev
Rheumatol. 7:321–329. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kakkar R, Hei H, Dobner S and Lee RT:
Interleukin 33 as a mechanically responsive cytokine secreted by
living cells. J Biol Chem. 287:6941–6948. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schmitz J, Owyang A, Oldham E, Song Y,
Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, et
al: IL-33, an interleukin-1-like cytokine that signals via the IL-1
receptor-related protein ST2 and induces T helper type 2-associated
cytokines. Immunity. 23:479–490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ali S, Huber M, Kollewe C, Bischoff SC,
Falk W and Martin MU: IL-1 receptor accessory protein is essential
for IL-33-induced activation of T lymphocytes and mast cells. Proc
Natl Acad Sci USA. 104:18660–18665. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu WT, Li MQ, Liu W, Jin LP, Li DJ and Zhu
XY: IL-33 enhances proliferation and invasiveness of decidual
stromal cells by up-regulation of CCL2/CCR2 via NF-κB and ERK1/2
signaling. Mol Hum Reprod. 20:358–372. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moulin D, Donzé O, Talabot-Ayer D, Mézin
F, Palmer G and Gabay C: Interleukin (IL)-33 induces the release of
pro-inflammatory mediators by mast cells. Cytokine. 40:216–225.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu X, Zhu L, Lu X, Bian H, Wu X, Yang W
and Qin Q: IL-33/ST2 pathway contributes to metastasis of human
colorectal cancer. Biochem Biophys Res Commun. 453:486–492. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu XX, Hu Z, Shen X, Dong LY, Zhou WZ and
Hu WH: IL-33 Promotes gastric cancer cell invasion and migration
via ST2-ERK1/2 pathway. Dig Dis Sci. 60:1265–1272. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bergis D, Kassis V, Ranglack A, Koeberle
V, Piiper A, Kronenberger B, Zeuzem S, Waidmann O and Radeke HH:
High Serum levels of the interleukin-33 receptor soluble ST2 as a
negative prognostic factor in hepatocellular carcinoma. Transl
Oncol. 6:311–318. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu LA, Fu Y, Zhang DN and Zhang J: Serum
IL-33 as a diagnostic and prognostic marker in non-small cell lung
cancer. Asian Pac J Cancer Prev. 14:2563–2566. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gadani SP, Walsh JT, Smirnov I, Zheng J
and Kipnis J: The glia-derived alarmin IL-33 orchestrates the
immune response and promotes recovery following CNS injury. Neuron.
85:703–709. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fang KM, Yang CS, Lin TC, Chan TC and
Tzeng SF: Induced interleukin-33 expression enhances the
tumorigenic activity of rat glioma cells. Neuro-oncol. 16:552–566.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang J, Wang P, Ji W, Ding Y and Lu X:
Overexpression of interleukin-33 is associated with poor prognosis
of patients with glioma. Int J Neurosci. 127:210–217. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ii M, Nishimura H, Iwakura A, Wecker A,
Eaton E, Asahara T and Losordo DW: Endothelial progenitor cells are
rapidly recruited to myocardium and mediate protective effect of
ischemic preconditioning via ‘imported’ nitric oxide synthase
activity. Circulation. 111:1114–1120. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Funakoshi-Tago M, Tago K, Hayakawa M,
Tominaga S, Ohshio T, Sonoda Y and Kasahara T: TRAF6 is a critical
signal transducer in IL-33 signaling pathway. Cell Signal.
20:1679–1686. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Radisky DC and Bissell MJ: Cancer. Respect
thy neighbor! Science. 303:775–777. 2004.PubMed/NCBI
|
|
29
|
Balkwill F, Charles KA and Mantovani A:
Smoldering and polarized inflammation in the initiation and
promotion of malignant disease. Cancer Cell. 7:211–217. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Milovanovic M, Volarevic V, Radosavljevic
G, Jovanovic I, Pejnovic N, Arsenijevic N and Lukic ML: IL-33/ST2
axis in inflammation and immunopathology. Immunol Res. 52:89–99.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim JY, Lim SC, Kim G, Yun HJ, Ahn SG and
Choi HS: Interleukin-33/ST2 axis promotes epithelial cell
transformation and breast tumorigenesis via upregulation of COT
activity. Oncogene. 34:4928–4938. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bergers G, Reikerstorfer A, Braselmann S,
Graninger P and Busslinger M: Alternative promoter usage of the
Fos-responsive gene Fit-1 generates mRNA isoforms coding for either
secreted or membrane-bound proteins related to the IL-1 receptor.
EMBO J. 13:1176–1188. 1994.PubMed/NCBI
|
|
34
|
Jovanovic IP, Pejnovic NN, Radosavljevic
GD, Pantic JM, Milovanovic MZ, Arsenijevic NN and Lukic ML:
Interleukin-33/ST2 axis promotes breast cancer growth and
metastases by facilitating intratumoral accumulation of
immunosuppressive and innate lymphoid cells. Int J Cancer.
134:1669–1682. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jovanovic I, Radosavljevic G, Mitrovic M,
Juranic VL, McKenzie ANJ, Arsenijevic N, Jonjic S and Lukic ML: ST2
deletion enhances innate and acquired immunity to murine mammary
carcinoma. Eur J Immunol. 41:1902–1912. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gao K, Li X and Zhang L, Bai L, Dong W,
Gao K, Shi G, Xia X, Wu L and Zhang L: Transgenic expression of
IL-33 activates CD8(+) T cells and NK cells and inhibits tumor
growth and metastasis in mice. Cancer Lett. 335:463–471. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Miller AM, Xu D, Asquith DL, Denby L, Li
Y, Sattar N, Baker AH, McInnes IB and Liew FY: IL-33 reduces the
development of atherosclerosis. J Exp Med. 205:339–346. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Barbour M, Allan D, Xu H, Pei C, Chen M,
Niedbala W, Fukada SY, Besnard AG, Alves-Filho JC, Tong X, et al:
IL-33 attenuates the development of experimental autoimmune
uveitis. Eur J Immunol. 44:3320–3329. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Besnard AG, Togbe D, Guillou N, Erard F,
Quesniaux V and Ryffel B: IL-33-activated dendritic cells are
critical for allergic airway inflammation. Eur J Immunol.
41:1675–1686. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Solinas G, Germano G, Mantovani A and
Allavena P: Tumor-associated macrophages (TAM) as major players of
the cancer-related inflammation. J Leukoc Biol. 86:1065–1073. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schmieder A, Multhoff G and Radons J:
Interleukin-33 acts as a pro-inflammatory cytokine and modulates
its receptor gene expression in highly metastatic human pancreatic
carcinoma cells. Cytokine. 60:514–521. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Markovic DS, Vinnakota K, Chirasani S,
Synowitz M, Raguet H, Stock K, Sliwa M, Lehmann S, Kälin R, van
Rooijen N, et al: Gliomas induce and exploit microglial MT1-MMP
expression for tumor expansion. Proc Natl Acad Sci USA.
106:12530–12535. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mentlein R, Hattermann K and Held-Feindt
J: Lost in disruption: Role of proteases in glioma invasion and
progression. Biochim Biophys Acta. 1825:178–185. 2012.PubMed/NCBI
|
|
45
|
Zheng X, Chopp M, Lu Y, Buller B and Jiang
F: MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis
via NRP-2 and MMP-3. Cancer Lett. 329:146–154. 2013. View Article : Google Scholar : PubMed/NCBI
|
